Aim: to detect the levels of CEC and expression of NFκB in the three groups of subjects with certain conditions.

Methods: this study is an exploratory study using human peripheral blood samples. The study subjects comprised three groups, the group of 23 healthy people, a group of 35 people that has one or more risk factors for vascular disease and a group of 15 vascular disease patients (coronary heart disease, diabetes mellitus, stroke). CEC were isolated from peripheral blood mononuclear cells (PBMC). CEC level is identified through the measurement of CD45 and CD146 by flowcytometry method. NFκB expression is recognized by ELISA method (imgenex, USA).

Results: the highest average levels of CEC were found in the sick group (28.6%). The highest average expression of NFκB (924.9495) is found in the group with risk factors. The lowest average expression of NFκB and CEC is found in the healthy group. Statistical analysis of ANOVA at the interval confidence of 95% shows a significant difference (p=0.00) levels of CEC and NFκB expression between the healthy group with the group with the risk of cardiovascular disease (CVD) and patients with known CVD.

Conclusion: increase of level CEC and NFκB expression has a strong relationship with vascular disease and its risk factors.

Download full-text PDF

Source

Publication Analysis

Top Keywords

peripheral blood
12
levels cec
12
expression nfκb
12
risk factors
12
vascular disease
12
nfκb expression
12
blood mononuclear
8
mononuclear cells
8
three groups
8
group
8

Similar Publications

In patients with transplant-eligible newly diagnosed multiple myeloma, induction therapy with a quadruplet regimen prior to autologous transplant is the standard of care. The phase III IFM2020-02-MIDAS study (NCT04934475) assessed a minimal residual disease (MRD)-driven consolidation and maintenance strategy following induction with isatuximab, carfilzomib, lenalidomide, and dexamethasone (IsaKRD). Here, we report safety and efficacy outcomes of six 28-day cycles of IsaKRD.

View Article and Find Full Text PDF

Human-induced pluripotent stem cell (hiPSC) technology has been applied in pathogenesis studies, drug screening, tissue engineering, and stem cell therapy, and patient-specific hiPSC-derived cardiomyocytes (hiPSC-CMs) have shown promise in disease modeling, including diabetic cardiomyopathy. High glucose (HG) treatment induces lipotoxicity in hiPSC-CMs, as evidenced by changes in cell size, beating rate, calcium handling, and lipid accumulation. Empagliflozin, an SGLT2 inhibitor, effectively mitigates the hypertrophic changes, abnormal calcium handling, and contractility impairment induced by HG.

View Article and Find Full Text PDF

CTCNet: a fine-grained classification network for fluorescence images of circulating tumor cells.

Med Biol Eng Comput

January 2025

Anhui BioX-Vision Biological Technology Co., Ltd, Hefei, 230031, Anhui, China.

The identification and categorization of circulating tumor cells (CTCs) in peripheral blood are imperative for advancing cancer diagnostics and prognostics. The intricacy of various CTCs subtypes, coupled with the difficulty in developing exhaustive datasets, has impeded progress in this specialized domain. To date, no methods have been dedicated exclusively to overcoming the classification challenges of CTCs.

View Article and Find Full Text PDF

Diagnostic imaging of Bacillus cereus brain infection in newborns.

Pediatr Radiol

January 2025

Pediatric Radiology Department, CHRU of Tours, Clocheville Hospital, 49 Boulevard Beranger, 37000, Tours, France.

Background: Cerebral infection with the opportunistic pathogen Bacillus cereus can lead to severe lesions, especially in premature newborns. Early diagnosis would be highly beneficial. The aim of this study was to describe the imaging findings associated with B.

View Article and Find Full Text PDF

Telomere shortening in donor cell-derived acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplantation: a case report.

Ann Hematol

January 2025

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-Ku, Tokyo, 113-8677, Japan.

Donor cell leukemia (DCL), in which malignancy evolves from donor's stem cells, is an infrequent complication of allogeneic hematopoietic stem cell transplantation. Acute promyelocytic leukemia (APL) derived from donor cell is extremely rare and only four cases have been reported to date. Herein we report a case of donor cell-derived APL developing 32 months after haploidentical peripheral blood stem cell transplantation using posttransplant cyclophosphamide for myelodysplastic syndromes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!